It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Influenza viruses are a major public health problem. Vaccines are the best available countermeasure to induce effective immunity against infection with seasonal influenza viruses; however, the breadth of antibody responses in infection versus vaccination is quite different. Here, we show that nasal infection controls two sequential processes to induce neutralizing IgG antibodies recognizing the hemagglutinin (HA) of heterotypic strains. The first is viral replication in the lung, which facilitates exposure of shared epitopes that are otherwise hidden from the immune system. The second process is the germinal center (GC) response, in particular, IL-4 derived from follicular helper T cells has an essential role in the expansion of rare GC-B cells recognizing the shared epitopes. Therefore, the combination of exposure of the shared epitopes and efficient proliferation of GC-B cells is critical for generating broadly-protective antibodies. These observations provide insight into mechanisms promoting broad protection from virus infection.
The reasons why influenza infection promotes a broader antibody response compared with vaccines are not fully understood. Here the authors show that unmasking of haemagglutinin epitopes and IL-4 signals in the germinal centre contribute to broader antibody responses after infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Laboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
2 National Institute of Infectious Diseases, Research Center for Drug and Vaccine Development, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880)
3 Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
4 Laboratory for Lymphocyte Differentiation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
5 Laboratory for Integrated Cellular Systems, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255); Institute for Advanced Biosciences, Keio University, Kanagawa, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Systems Biology Program, Graduate School of Media and Governance, Keio University, Kanagawa, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
6 Center for Animal Disease Models, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
7 Keio University School of Medicine, Department of Microbiology and Immunology, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
8 Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880)
9 Laboratory for Integrated Cellular Systems, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255); Institute for Advanced Biosciences, Keio University, Kanagawa, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
10 Laboratory for Immunotherapy, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
11 Laboratory for Integrative Genomics, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
12 Laboratory for Cytokine Regulation, Research Center for Integrative Medical Sciences (IMS), RIKEN Yokohama Institute, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255); Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)